The purpose of the study is to see whether daridorexant can help improve sleep in people with depression and insomnia, and to check its safety. The study is organized as a double-blind and randomized trial, which means the treatment is assigned by chance and neither the participants nor the study team know which treatment is given during the study. Treatment lasts about 3 months, and sleep and mood are checked during this time to see how the medicine works and whether any side effects occur.

During the study, participants will be divided into two groups. One group will receive tasimelteon as an oral liquid suspension, while the other group will receive a placebo liquid that looks exactly the same. The treatment will continue for 12 months, with participants taking their assigned medication daily. The amount of medicine given will be based on the participant’s weight, but will not exceed 20 milligrams per day.

Throughout the study, information about sleep patterns will be collected through daily sleep diaries that participants and their caregivers will need to complete. Various aspects of sleep and daily functioning will be monitored, including how long it takes to fall asleep and how well participants feel during the day. The study will also look at how the medicine affects the youngest participants who are two years old.

The purpose of this research is to determine how well these treatments work in reducing depression symptoms when used over an 8-week period. During the study, participants will be divided into different groups, with some receiving melatonin, some receiving light therapy, some receiving both treatments, and others receiving placebo. The treatment period lasts for 8 weeks, with regular check-ups to monitor participants’ progress.

Throughout the study, doctors will assess changes in depression symptoms and sleep patterns. They will use various methods to measure improvements in mood and sleep quality. The total amount of melatonin that participants might receive during the entire study period is 112 mg, taken as daily doses of 2 mg in the form of prolonged-release tablets.

Participants in the study will be randomly assigned to receive either melatonin, quetiapine, or a placebo. The treatment will be given in the form of film-coated tablets, which are taken orally. The study will last for a period of six months, during which the effects of the treatments on sleep and overall well-being will be monitored. The study aims to provide insights into which treatment might be more effective in managing insomnia in adolescents with psychiatric conditions.

Throughout the study, various aspects of the participants’ sleep and mental health will be assessed. This includes measuring the severity of insomnia using the Insomnia Severity Index, evaluating sleep quality, and assessing psychosocial functioning and subjective well-being. The study will also look at how the treatments affect rest-sleep-activity cycles and other physiological variables. The findings from this study could help improve treatment options for young people dealing with both psychiatric disorders and sleep difficulties.

Participants in the study will take daridorexant daily as part of their regular treatment. The study will monitor changes in their sleep patterns and daytime symptoms over a period of six months. This will include visits at three months and six months to assess how the medication is working. During these visits, changes in sleep quality and cognitive performance, such as attention and memory, will be evaluated using simple tests and questionnaires.

The study aims to provide a better understanding of how daridorexant can help improve sleep and daily functioning in people with chronic insomnia. By observing changes in sleep and cognitive performance, researchers hope to gather valuable information on the benefits of this treatment for those affected by this sleep disorder.

The purpose of the study is to evaluate how effective these treatments are, both individually and in combination, in improving sleep and mood in women experiencing perimenopause. Participants will use the hormone therapy and the online program over a period of time, and their progress will be monitored. The study will also use devices like the Hypnodyne ZMax Total and the Empatica EmbracePlus wristband to track sleep patterns and other health indicators at home.

The study will last several months, with participants being assessed at different stages to see how their symptoms change over time. The goal is to find ways to reduce mental health complaints and improve overall well-being for women going through perimenopause. This research aims to provide valuable insights into managing symptoms associated with this phase of life.

The purpose of the study is to investigate the effect of CBD on MS patients with impaired sleep quality. Participants will take part in a series of 15 individual trials, where they will receive either the CBD oil or a placebo over a period of time. Throughout the study, participants will be asked to keep a daily diary to record their sleep patterns and any other experiences they have. This will help researchers understand how CBD might improve sleep quality in people with MS.

Participants will also use a mobile app called the Neurokeys app to help track their sleep and other related outcomes. The study will look at various aspects of sleep, such as how long it takes to fall asleep, the number of times a person wakes up during the night, and the total amount of sleep time. By the end of the study, researchers hope to gather valuable information on whether CBD can be a helpful treatment for improving sleep in people with MS.

Participants in the study will be given either Neurexan or a placebo, which looks like the medication but does not contain any active ingredients. The study will monitor how well participants sleep using a method called polysomnography, which records brain waves, oxygen levels, heart rate, and breathing during sleep. Additionally, participants will report their sleep patterns and daytime performance through questionnaires. The study will also look at stress response by measuring certain markers in the body.

The trial will take place over a period of time, with participants taking the medication daily. The goal is to determine if Neurexan can improve sleep and reduce stress in people with short-term insomnia. This study is exploratory, meaning it is designed to gather more information about how Neurexan works in improving sleep and managing stress. Participants will be closely monitored throughout the study to ensure their safety and to collect accurate data on the effects of the treatment.

The purpose of the study is to understand how different doses of daridorexant affect sleep in young people with insomnia. The study will involve multiple doses of the medication, and participants will be monitored to see how their sleep changes over time. This will be done using a method called polysomnography, which is a type of sleep study that records brain waves, oxygen levels, heart rate, and breathing during sleep.

Participants will take the medication or placebo for a period of up to 20 days. The study will help determine the best dose of daridorexant for improving sleep in children and adolescents with insomnia. The results will provide valuable information on the safety and effectiveness of this treatment for young people struggling with sleep difficulties.

The purpose of the study is to evaluate how well the Escholzia tablets improve sleep quality and how safe they are for use. The study is divided into two phases. In the first phase, participants will be randomly assigned to receive either the Escholzia tablets or the placebo for one month. This phase is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. In the second phase, all participants will receive the Escholzia tablets for an additional two months to further assess the treatment’s safety and effectiveness.

Throughout the study, participants will be asked to keep a daily sleep diary and may wear a device to monitor their sleep patterns. The study will also look at changes in daytime sleepiness, mood, and overall quality of life. Additionally, some participants may provide saliva samples to measure levels of certain hormones related to stress and sleep. The study aims to provide valuable information on how Escholzia tablets can help people with insomnia improve their sleep and overall well-being.

Participants in the study will receive either the medication QUVIVIQ, which contains daridorexant, or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be a double-blind, randomized, placebo-controlled trial, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the study period. This helps ensure that the results are unbiased and reliable.

The study will take place over several weeks, during which participants will be monitored to see how their sleep patterns change. The main goal is to assess whether daridorexant can increase the total amount of sleep time for those with insomnia and nocturia. Participants will be asked to report their sleep experiences, and researchers will analyze this information to determine the effectiveness of the treatment. The study is expected to provide valuable insights into managing sleep disorders in individuals with these conditions.

The purpose of the study is to evaluate how effective tasipimidine is in helping patients with insomnia disorder. Participants in the study will take the medication at bedtime for three consecutive nights. Throughout the study, researchers will monitor various aspects of sleep, such as how long it takes to fall asleep and how often participants wake up during the night. The study will also keep track of any side effects and changes in vital signs like heart rate and blood pressure.

Participants will be asked to report their experiences and any changes in their sleep patterns. The study aims to provide valuable information on the potential benefits and safety of tasipimidine for treating insomnia disorder.

The study will involve taking the medication in the form of film-coated tablets by mouth. The treatment period will last for several months, during which the participants’ sleep patterns will be monitored. This will help researchers understand how the medication affects the total sleep time and other sleep-related factors. The study will also look at how the medication impacts other aspects of health, such as mood, memory, and overall quality of life.

Throughout the study, participants will undergo various assessments to track changes in their sleep and cognitive functions. These assessments may include sleep studies using a method called polysomnography, which records brain waves, oxygen levels, heart rate, and breathing during sleep. The study aims to provide valuable insights into the potential benefits of daridorexant for improving sleep and related symptoms in patients with insomnia and Alzheimer’s disease.

Participants in the study will be randomly assigned to receive either melatonin, low-dose quetiapine, or a placebo. The study will last for a period of six months, during which participants will take the assigned treatment orally in the form of film-coated tablets. Throughout the study, participants will be monitored to assess the severity of their insomnia and their overall well-being.

The trial aims to provide insights into how these treatments can help improve sleep quality and daily functioning in individuals with psychiatric disorders and insomnia. By comparing the effects of melatonin and quetiapine to a placebo, researchers hope to determine the most effective approach to managing these conditions together.

The purpose of the study is to determine if low dose amitriptyline is as effective as cognitive behavioral therapy for insomnia (CBT-I), a type of therapy that helps people change their thoughts and behaviors around sleep. Participants in the study will either receive the medication or undergo CBT-I. The study will last for a period of 12 weeks, during which the participants’ sleep patterns and daytime functioning will be monitored to assess the effectiveness of the treatment.

Throughout the study, researchers will collect information on how well participants sleep, their overall sleep quality, and how they function during the day. They will also monitor any side effects or withdrawal symptoms from the treatment. The goal is to see if amitriptyline can be a viable alternative to CBT-I for people with chronic insomnia and other medical conditions.